Advertisement

Bone-Targeted Therapy for Prostate Cancer

  • Navjeet Gandhok
  • Oliver Sartor
Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

Both prostate cancer and treatments for prostate cancer have potentially harmful effects on bone. Prostate cancer reliably metastasizes to bone in its advanced stages, and these metastatic deposits have a variety of deleterious effects on patients including pain and pathologic fractures. In addition, commonly utilized androgen deprivation strategies used in prostate cancer treatment reduce bone mineral density, which in turn can lead to osteopenia or osteoporosis with its attendant risks. Thus, a relatively unique series of relationships exists in prostate cancer patients among the bone, the cancer, and commonly administered treatments.

Keywords

Prostate Cancer Bone Mineral Density Bone Metastasis Prostate Cancer Cell Zoledronic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Corey E, Arfman EW, Oswin MM, et al. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997; 50: 184–188.PubMedCrossRefGoogle Scholar
  2. 2.
    Ghossein RA, Scher HI, Gerald WL, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195–1200.PubMedGoogle Scholar
  3. 3.
    Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003; 21: 490–495.PubMedCrossRefGoogle Scholar
  4. 4.
    Glaves D. Mechanisms of metastasis: prostate cancer. Prog Clin Biol Res 1987; 239: 329–345.PubMedGoogle Scholar
  5. 5.
    Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 1984; 54: 3078–3084.PubMedCrossRefGoogle Scholar
  6. 6.
    Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578–583.PubMedCrossRefGoogle Scholar
  7. 7.
    Figg WD, Ammerman K, Patrona N, et al. Lack of correlation between PSA and the presence of measurable soft tissue metastases in hormone refractory prostate cancer. Cancer Invest 1996; 14: 513–517.PubMedCrossRefGoogle Scholar
  8. 8.
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 571–573.Google Scholar
  9. 9.
    Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832–1837.PubMedGoogle Scholar
  10. 10.
    Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003; 97 (3 suppl): 772–778.PubMedCrossRefGoogle Scholar
  11. 11.
    Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17–25.PubMedCrossRefGoogle Scholar
  12. 12.
    Carruba G, Stefano R, Cocciadiferro L, et al. Intercellular communication and human prostate carcinogenesis. Ann NY Acad Sci 2002; 963: 156–168.PubMedCrossRefGoogle Scholar
  13. 13.
    Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453–4457.PubMedGoogle Scholar
  14. 14.
    Habermann H, Ray V, Habermann W, Prins GS. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 2002; 167: 655–660.PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper CR, Chay CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003; 97 (3 suppl): 739–747.PubMedCrossRefGoogle Scholar
  16. 16.
    Mohan S, Baylink DJ. Bone growth factors. Clin Orthop 1991; 263: 30–48.PubMedGoogle Scholar
  17. 17.
    Nissinen L, Pirila L, Heino J. Bone morphogenetic protein-2 is a regulator of cell adhesion. Exp Cell Res 1997; 230: 377–385.PubMedCrossRefGoogle Scholar
  18. 18.
    Thomas BG, Hamdy FC. Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate. Prostate Cancer Prostatic Dis 2000; 3: 283–285.PubMedCrossRefGoogle Scholar
  19. 19.
    Kostenuik PJ, Singh G, Orr FW. Transforming growth factor beta upregulates the integrin mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 1997; 15: 41–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Bello-DeOcampo D, Tindall DJ. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 2003; 4: 197–207.PubMedCrossRefGoogle Scholar
  21. 21.
    Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003; 30: 263–277.PubMedCrossRefGoogle Scholar
  22. 22.
    Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002; 38: 91–102.CrossRefGoogle Scholar
  23. 23.
    Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235–1244.PubMedCrossRefGoogle Scholar
  24. 24.
    Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944–949.PubMedCrossRefGoogle Scholar
  25. 25.
    Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97 (3 suppl): 779–784.PubMedCrossRefGoogle Scholar
  26. 26.
    Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584–593.Google Scholar
  27. 27.
    Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer—Genitourinary Group Study 30853. Cancer 1993; 72 (12 suppl): 3793–3798.Google Scholar
  28. 28.
    Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30: 377–401.PubMedCrossRefGoogle Scholar
  29. 29.
    Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713–1717.PubMedGoogle Scholar
  30. 30.
    Jacobson AF, Cronin EB, Stomper PC, Kaplan WD. Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990; 175: 229–232.PubMedGoogle Scholar
  31. 31.
    Hadley D, Fowble B, Torosian MH. Evidence for selective use of bone scans in early stage breast cancer. Oncol Rep 1998; 5: 991–993.PubMedGoogle Scholar
  32. 32.
    Tumeh SS, Beadle G, Kaplan WD. Clinical significance of solitary rib lesions in patients with extraskeletal malignancy. J Nucl Med 1985; 26: 1140–1143.PubMedGoogle Scholar
  33. 33.
    Wu PS, Chiu NT, Lee BF, Yao WJ, W Chen HH. Clinical significance of solitary rib hot spots on bone scans in patients with extraskeletal cancer: correlation with other clinical manifestations. Clin Nucl Med 2002; 27: 567–571.PubMedCrossRefGoogle Scholar
  34. 34.
    Jacobson AF, Stomper PC, Jochelson MS, Ascoli DM, Henderson IC, Kaplan WD. Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer. J Nucl Med 1990; 31: 387–392.PubMedGoogle Scholar
  35. 35.
    Stege R. Potential side effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 2000; 10: 38–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Ornstein DK, Beiser JA, Andriole GL. Anemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83: 43–46.PubMedCrossRefGoogle Scholar
  37. 37.
    Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy; Prostate 1996; 29: 243–248.PubMedCrossRefGoogle Scholar
  38. 38.
    Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity; Urology 2003; 61 (2 suppl 1): 32–38.Google Scholar
  39. 39.
    Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcemia of malignancy; Drugs 2003; 63: 417–437.Google Scholar
  40. 40.
    Saad F, Gleason DM, Murray R, et al. Zoledronic acid Prostate Cancer Study Group. J Natl Cancer Inst 2002; 94: 1458–1468.PubMedCrossRefGoogle Scholar
  41. 41.
    Rosen LS. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 2002; 29 (6 suppl 21): 28–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168: 2444–2450.PubMedCrossRefGoogle Scholar
  43. 43.
    Sartor O. Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr Oncol Rep 2003; 5: 258–262.PubMedCrossRefGoogle Scholar
  44. 44.
    Mertens WC, Filipczak LA, Ben-Josef E. Systemic bone-seeking radionuclides for palliation of painful osseous metastases; current concepts. CA Cancer J Clin 1998; 48: 361–374.PubMedCrossRefGoogle Scholar
  45. 45.
    Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954–958.PubMedCrossRefGoogle Scholar
  46. 46.
    Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988; 14: 349–351.PubMedCrossRefGoogle Scholar
  47. 47.
    Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574–1581.PubMedGoogle Scholar
  49. 49.
    Sartor O, Quick D, Reid R. A double blind placebo controlled study of 153-Samarium-EDTMP for palliation of bone pain in patients with hormone refractory prostate cancer. Presented at the 92nd Annual Meeting of the American Urological Association, 1997 (abstract 1252 ).Google Scholar
  50. 50.
    Maxon HR 3rd, Schroder LE, Washburn LC, et al. Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med 1998; 39: 659–663.PubMedGoogle Scholar
  51. 51.
    Kossman SE, Weiss MA. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer 2000; 88: 620–624.PubMedCrossRefGoogle Scholar
  52. 52.
    Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805–813.PubMedCrossRefGoogle Scholar
  53. 53.
    Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001; 357: 336–341.PubMedCrossRefGoogle Scholar
  54. 54.
    Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43: 79–86.PubMedGoogle Scholar
  55. 55.
    Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80 (8 suppl): 1652–1660.PubMedCrossRefGoogle Scholar
  56. 56.
    Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol 1994; 21: 630–656.PubMedGoogle Scholar
  57. 57.
    Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983; 51: 918–924.PubMedCrossRefGoogle Scholar
  59. 59.
    Ikeda T, Lioubin MN, Marquardt H. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 1987; 26: 2406–2410.PubMedCrossRefGoogle Scholar
  60. 60.
    Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996; 132: 195–210.PubMedCrossRefGoogle Scholar
  61. 61.
    Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–3894.PubMedGoogle Scholar
  62. 62.
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488–493.PubMedCrossRefGoogle Scholar
  63. 63.
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785–1791.PubMedCrossRefGoogle Scholar
  64. 64.
    Lipton A, Small E, Saad F, et al. The new bisphosphonate, ZometaTM (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparison to pamidronate [abstract 34]. Cancer Invest 2001; 20: 45–47.CrossRefGoogle Scholar
  65. 65.
    Dearnaley DP, Sydes MR, on behalf of the MRC Pr05 Collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 Trial [abstract]. Proc ASCO 2001; 20: 174a.Google Scholar
  66. 66.
    Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–387.PubMedGoogle Scholar
  67. 67.
    Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.PubMedCrossRefGoogle Scholar
  68. 68.
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 858–864.PubMedCrossRefGoogle Scholar
  69. 69.
    Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 1996; 77: 102–106.PubMedCrossRefGoogle Scholar
  70. 70.
    Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized phase II placebo controlled trial. J Clin Oncol 2003; 21: 679–689.PubMedCrossRefGoogle Scholar
  71. 71.
    Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97 (3 suppl): 887–892.PubMedCrossRefGoogle Scholar
  72. 72.
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439–444.PubMedCrossRefGoogle Scholar
  73. 73.
    Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma: Cancer 1997; 79: 545–550.PubMedCrossRefGoogle Scholar
  74. 74.
    Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449–452.PubMedCrossRefGoogle Scholar
  75. 75.
    Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724–1728.PubMedCrossRefGoogle Scholar
  76. 76.
    Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167: 1952–1956.PubMedCrossRefGoogle Scholar
  77. 77.
    Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003; 97 (3 suppl): 789–795.PubMedCrossRefGoogle Scholar
  78. 78.
    Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; 61: 127–131.PubMedCrossRefGoogle Scholar
  79. 79.
    Scherr D, Pitts WR, Jr, Vaughn ED Jr. Diethylstilbestrol revisited: androgen deprivation, osteoporosis, and prostate cancer. J Urol 2002; 168: 1506–1507.Google Scholar
  80. 80.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–955.PubMedCrossRefGoogle Scholar
  81. 81.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol 2003; 169: 2008–2012.PubMedCrossRefGoogle Scholar
  82. 82.
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604–610.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Navjeet Gandhok
  • Oliver Sartor

There are no affiliations available

Personalised recommendations